C4 Therapeutics (NASDAQ:CCCC) Given “Overweight” Rating at Stephens

Stephens restated their overweight rating on shares of C4 Therapeutics (NASDAQ:CCCC) in a research note issued to investors on Monday morning,Benzinga reports. The firm currently has a $6.00 price objective on the stock.

Other equities analysts have also issued research reports about the stock. Barclays reissued an “overweight” rating and issued a $10.00 price target on shares of C4 Therapeutics in a report on Monday. Guggenheim started coverage on shares of C4 Therapeutics in a report on Wednesday, September 3rd. They issued a “buy” rating and a $8.00 price target on the stock. Wall Street Zen lowered shares of C4 Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Finally, Zacks Research lowered shares of C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 22nd. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

C4 Therapeutics Price Performance

NASDAQ CCCC opened at $2.61 on Monday. C4 Therapeutics has a 1 year low of $1.09 and a 1 year high of $7.14. The stock has a market capitalization of $185.75 million, a PE ratio of -1.65 and a beta of 2.98. The company’s 50 day simple moving average is $2.52 and its two-hundred day simple moving average is $1.91.

C4 Therapeutics (NASDAQ:CCCC) last posted its earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.01. C4 Therapeutics had a negative net margin of 325.88% and a negative return on equity of 53.91%. The business had revenue of $6.46 million for the quarter, compared to analysts’ expectations of $5.24 million. On average, research analysts anticipate that C4 Therapeutics will post -1.52 EPS for the current year.

Hedge Funds Weigh In On C4 Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Dynamic Technology Lab Private Ltd bought a new position in shares of C4 Therapeutics during the 2nd quarter valued at $31,000. Savant Capital LLC bought a new position in shares of C4 Therapeutics during the 2nd quarter valued at $38,000. Catalyst Funds Management Pty Ltd bought a new position in shares of C4 Therapeutics during the 2nd quarter valued at $40,000. Crestwood Advisors Group LLC bought a new position in shares of C4 Therapeutics during the 2nd quarter valued at $41,000. Finally, Brookstone Capital Management bought a new position in shares of C4 Therapeutics during the 2nd quarter valued at $42,000. Institutional investors own 78.81% of the company’s stock.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.